| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | 178.92% | Needham | → $34 | Reiterates | Buy → Buy |
| 09/12/2023 | 211.73% | Wedbush | → $38 | Reiterates | Outperform → Outperform |
| 09/12/2023 | 178.92% | Needham | → $34 | Reiterates | Buy → Buy |
| 08/08/2023 | 178.92% | Needham | → $34 | Reiterates | → Buy |
| 08/08/2023 | 342.99% | Goldman Sachs | $63 → $54 | Maintains | Buy |
| 08/08/2023 | 310.17% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy |
| 06/05/2023 | 211.73% | Wedbush | → $38 | Reiterates | Outperform → Outperform |
| 06/05/2023 | 228.14% | Needham | → $40 | Reiterates | Buy → Buy |
| 06/05/2023 | 310.17% | HC Wainwright & Co. | $45 → $50 | Maintains | Buy |
| 05/18/2023 | 269.16% | HC Wainwright & Co. | → $45 | Reiterates | Buy → Buy |
| 05/08/2023 | 228.14% | Needham | $44 → $40 | Maintains | Buy |
| 05/02/2023 | 260.95% | Needham | → $44 | Reiterates | → Buy |
| 04/25/2023 | -26.17% | B of A Securities | $34 → $9 | Downgrades | Buy → Underperform |
| 04/05/2023 | 260.95% | Needham | $48 → $44 | Maintains | Buy |
| 03/07/2023 | 293.77% | Needham | → $48 | Reiterates | → Buy |
| 03/07/2023 | 269.16% | HC Wainwright & Co. | → $45 | Reiterates | → Buy |
| 02/08/2023 | 228.14% | Capital One | → $40 | Initiates Coverage On | → Overweight |
| 02/03/2023 | — | Oppenheimer | Initiates Coverage On | → Perform | |
| 01/09/2023 | 408.61% | Goldman Sachs | $45 → $62 | Maintains | Buy |
| 01/09/2023 | 269.16% | Piper Sandler | $40 → $45 | Maintains | Overweight |
| 01/09/2023 | 269.16% | HC Wainwright & Co. | $35 → $45 | Maintains | Buy |
| 12/15/2022 | 187.12% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
| 12/14/2022 | 228.14% | Needham | → $40 | Initiates Coverage On | → Buy |
| 12/05/2022 | 269.16% | Goldman Sachs | → $45 | Initiates Coverage On | → Buy |
| 12/01/2022 | 178.92% | B of A Securities | → $34 | Initiates Coverage On | → Buy |
| 06/21/2022 | 228.14% | Piper Sandler | $35 → $40 | Maintains | Overweight |
| 06/14/2022 | 187.12% | Wedbush | $32 → $35 | Maintains | Outperform |
| 06/21/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 06/21/2021 | 146.1% | Wedbush | → $30 | Initiates Coverage On | → Outperform |
| 06/21/2021 | 211.73% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
| 06/21/2021 | 260.95% | Piper Sandler | → $44 | Initiates Coverage On | → Overweight |
What is the target price for Day One Biopharmaceutical (DAWN)?
The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Needham on November 7, 2023. The analyst firm set a price target for $34.00 expecting DAWN to rise to within 12 months (a possible 178.92% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Day One Biopharmaceutical (DAWN)?
The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Needham, and Day One Biopharmaceutical reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Day One Biopharmaceutical (DAWN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
Is the Analyst Rating Day One Biopharmaceutical (DAWN) correct?
While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $0.00 to $34.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $12.19, which is within the analyst's predicted range.